REMS vs. Labeling-only Strategy For Teratogenic Drugs Goes Before Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Drug Safety and Risk Management Advisory Committee will weigh in on which factors are most important in FDA’s proposed framework on how to manage a drug’s potential to cause birth defects.